Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Neuren Pharmaceuticals Limited ( (AU:NEU) ) has provided an announcement.
Neuren Pharmaceuticals Limited announced a daily update on its ongoing on-market buy-back program, with a total of 17,081 ordinary fully paid securities bought back on the previous day. This buy-back initiative is part of the company’s strategy to manage its capital structure and potentially enhance shareholder value.
The most recent analyst rating on (AU:NEU) stock is a Buy with a A$30.65 price target. To see the full list of analyst forecasts on Neuren Pharmaceuticals Limited stock, see the AU:NEU Stock Forecast page.
More about Neuren Pharmaceuticals Limited
Neuren Pharmaceuticals Limited operates in the pharmaceutical industry, focusing on the development of therapies for neurological disorders. The company’s primary products are aimed at addressing unmet medical needs in this specialized market.
YTD Price Performance: 5.52%
Average Trading Volume: 781,635
Technical Sentiment Signal: Buy
Current Market Cap: A$1.68B
Find detailed analytics on NEU stock on TipRanks’ Stock Analysis page.